; and (2) submit to the committees specified in subsection (c) and post on the public website of the Food and Drug Administration an updated report under subsection (c). (e) Statement To accompany guidelines and recommendations The Commissioner of Food and Drugs shall ensure that any opioid analgesic prescribing guidelines and other recommendations developed under this section are accompanied by a clear statement that such guidelines or recommendations, as applicable— (1) are intended to help inform clinical decisionmaking by prescribers and patients; and (2) should not be used by other parties, including pharmacy benefit management companies, retail or community pharmacies, or public and private payors, for the purposes of restricting, limiting, delaying, or denying coverage for or access to a prescription issued for a legitimate medical purpose by an individual practitioner acting in the usual course of professional practice. (f) Definition In this section, the term evidence-based means informed by a robust and systemic review of treatment efficacy and clinical evidence. 3005. Report on opioids prescribing practices for pregnant women (a) In general Not later than 180 days after the date of the enactment of this Act, the Secretary of Health and Human Services, in coordination with the Centers for Disease Control and Prevention, the National Institutes of Health, and the Substance Abuse and Mental Health Services Administration shall develop and submit to the Congress a report— (1) on opioids prescribing practices for pregnant women and recommendations for such practices; (2) that provides recommendations for identifying and reducing opioids misuse during pregnancy; (3) on prescription opioid misuse during pregnancy in urban and rural areas; (4) on prescription opioid use during pregnancy for the purpose of medication-assisted treatment in urban and rural areas; (5) evaluating current utilization of non-opiate pain management practices in place of prescription opioids during pregnancy